Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trials

Human Vaccines

Volumn 5, Issue 7, 2009, Pages 483-487

  Sharma, Hitt J ^a   Multani, Amrik S ^b   Dutta, Ashok K ^c   Joshi, Surekha M ^d   Malik, Sushma ^d   Bhardwaj, Subodh ^a   Chakravarty, Anita ^e   Namjoshi, Gajanan S ^a   Parekh, Sameer ^a   Verma, Vikas ^e  

^a Serum Institute of India Ltd   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

^c KALAWATI SARAN CHILDREN'S HOSPITAL   (India)

^d BYL NAIR CHARITABLE HOSPITAL   (India)

^e MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Haemophilus influenzae type b; Immunogenicity; India; PRP T; Safety

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HIBPRO; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDING BEHAVIOR; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INDIA; INFANT; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LICENSING; MALE; MOUSE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NONHUMAN; OTITIS MEDIA; PATHOLOGICAL CRYING; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; RAT; RESTLESSNESS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; VACCINATION; VACCINE PRODUCTION;

EID: 70349549871     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.8582     Document Type: Article

References (30)

1. Introduction of Haemophilus influenzae type b vaccine into immunization programmes. Management guidelines, including information for health workers and parents. WHO Department of Vaccines and Biologicals 2000.
2. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006; 81:445-52.
3. Vuori-Holopainen E, Peltola H. Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin Infect Dis 2001; 32:715-26.
4. Olarte DG, Trujillo HS, Uribe AP, Agudelo AO. Lung puncture aspiration as a bacteriologic diagnostic procedure in acute pneumonias of infants and children. Clin Pediatr 1971; 10:346-50.
5. Peltola H. Haemophilus influenzae type b disease and vaccination in Latin America and the Caribbean. Pediatr Infect Dis J 1997; 16:780-7.
6. Takala AK, Eskola J, Leinonen M, Käyhty H, Nissinen A, Pekkanen E, Mäkelä PH. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991; 164:982-6.
7. Giovanni Gallo, Marta Luisa Ciofi degli Atti, Marina Cerquetti, Cinzia Piovesan, Alberto Eugenio Tozzi and Stefania Salmaso. Impact of a regional Hib vaccination programme in Italy. Vaccine 2002; 20:993-5.
8. Perdue DG, Bulkow LR, Gellin BG, Davidson M, Petersen KM, Singleton RJ, Parkinson AJ. Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. JAMA 2000; 283:3089-94.
9. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, et al. Elimination of Haemophilus influenzae Type B (Hib) Disease from The Gambia after the Introduction of Routine Immunization with a Hib Conjugate Vaccine: A Prospective Study. Lancet 2005; 366:144-50.
10. Lewis RF, Kisakye A, Gessner BD, Duku C, Odipio JB, Iriso R, et al. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bulletin of the World Health Organization. April 2008; 86:292-3.
11. Cowgill KD, Ndiritu M, Nyiro J, Slack MPE, Chiphatsi S, Ismail A, et al. Effectiveness of Haemophilus influenzae Type b Conjugate Vaccine Introduction Into Routine Childhood Immunization in Kenya. JAMA 2006; 296:671-8.
12. Baqui A, Arifeen SE, Saha SK, Persson L, Zaman K, Gessner BD, et al. Effectiveness of Haemophilus influenzae Type B Conjugate Vaccine on Prevention of Pneumonia and Meningitis in Bangladeshi Children: A Case-Control Study. Pediatric Infectious Disease Journal 2007; 26:565-71.
13. WHO Vaccine preventable diseases: monitoring system. Global summary 2007.
14. UNICEF. The state of the world's children 2006.
15. Invasive bacterial infections surveillance (IBIS) group of the International clinical epidemiology network. Are Haemophilus influenzae infections a significant problem in India? A prospective study and review. Clin Infect Dis 2002; 34:949-57.
16. Singhi P, Bansal A, Geeta P, Singhi S. Predictors of long term neurological outcome in bacterial meningitis. Indian Journal pediatrics 2007; 74:369-74.
17. Invasive Haemophilus influenzae disease in India: A preliminary report of prospective multi hospital surveillance. IBIS Ped Inf Dis J 1998; 17:172-5.
18. John TJ, Cherian T, Raghupathy P. Haemophilus influenza disease in children in India: A hospital perspective. Ped Inf Dis J 1998; 17:169-71.
19. Singh R, Thomas S, Kirubakaran C, Lalitha MK, Raghupathy. Occurrence of multiple antimicrobial resistance among Haemophilus influenzae type 'b' is causing meningitis. Indian J Med Res 1992; 95:230-3.
20. Nag VL, Ayyagari A, Venkatesh V, Ghar M, Yadav V, Prasad KN. Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India. Indian J Chest Dis Allied Sci 2001; 43:13-8.
21. Shapiro ED, Ward JI. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol Rev 1991; 13:113-42.
22. Saha SK, Khan WA, Saha S. Blood cultures from Bangladeshi children with septicemia: an evaluation of conventional, lysis-direct plating and lysis-centrifugation methods. Trans R Soc Trop Med Hyg 1992; 86:554-6.
23. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomized trial of Haemophilus influenzae type b tetanus protein conjugate vaccine prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349:1191-7.
24. Cochi SL, O'Mara D, Preblud SR. Progress in Haemophilus type b polysaccharide vaccine use in the United States. Pediatrics 1988; 81:166-8.
25. Global Immunization Data. 2008; WHO/UNICEF.
26. Indian Academy of Pediatrics. Guidebook on Immunization 2005 2006.
27. Phadke MA, Kulkarn MV, Sovani VB, Lokeshwar MR, Venkataraman R. Immunogenicity study of Haemophilus influenzae type b conjugate vaccine in Indian infants. Indian Pediatrics 1997; 34:779-83.
28. Fritzell B. Polysachharide vaccine against Haemophilus influenzae b conjugated to tetanus protein. Immunol Med 1991; 8:176-83.
29. Capeding MRZ. Immunogenicity of Haemophilus influenzae b conjugate vaccines in developing countries. JAMA 1994; 10:156-8.
30. Background rates of adverse events following immunization, Part 2 Supplementary information on vaccine safety WHO/V&B/00.36 2000.